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1. ABSTRACT 
 
Cholestatic liver diseases are characterized by blockade of bile flow from the liver to the intestine, and accumulation of 
hydrophobic bile acids in the liver and plasma. As a consequence an inflammatory response evolves associated with increased 
apoptosis, oxidative stress, and eventually fibrosis. Cholestasis is associated with profound metabolic changes, alterations in the 
mitochondrial function, decreased fatty acid oxidation, and increased glycolisis. Mitochondria play a central role in the 
development of this liver disease because they mediate death receptor signaling - triggered by inflammatory cytokines or bile 
acids - and contribute to oxidative damage, metabolic disorder, and onset of fibrosis. During the pathogenesis of biliary cirrhosis 
mitochondria’s need for renewal is hampered by a blunted mitochondrial biogenesis. Lack of stimulation of mitochondrial 
renewal helps to explain mitochondrial impairment in long-term cholestasis. The marked depletion of mitochondrial DNA and 
occurrence of mitochondrial DNA deletions are probably relevant contributors to the progression of this severe disease. All these 
findings certainly support the consideration of long-term cholestasis as a secondary mitochondrial hepatopathy. 
 
2. CHOLESTATIC LIVER DISEASES 
 
Cholestasis literally means “standing still of bile”, and is defined as any condition that causes retention and 
accumulation of potentially toxic bile acids in the liver and the systemic circulation 1. Cholestasis can be triggered by different 
causes, such as inflammation, viral infection, autoimmune diseases, gallstones, or tumors of the pancreas, liver or biliary tree. 
The origin of the hepatic damage can generally be hepatocellular – ascribed to a functional defect in bile formation mainly due to 
genetic mutations – or ductular/ductal (referred as obstructive jaundice) – caused by an impairment of bile secretion at the level 
of the bile ducts – 2-4. 
 
Cholestasis is responsible for severe biochemical and structural alterations of several organs, being the liver the most 
affected. Chronic cholestasis results in profound changes in liver architecture – fibrosis and increase in bile ductules – 5, 6, 
morphology – hepatomegaly and appearance of regenerative nodules – 6, and physiology – decreased enterohepatic circulation of 
bile acids and synthesis of albumin, portal hypertension - 6, 7. From a biochemical point of view, in cholestasis there is a shift in 
the mechanisms of energy production, since an alteration of mitochondrial function in the liver is associated with an increase in 
the glycolitic activity to cope with energy needs. 
 
Experimentally, cholestasis is usually studied in rodents, but also in rabbits and dogs, by the use of surgical 
intervention of common bile duct ligation (BDL or CBDL) 8, 9. This technique simulates an extrahepatic cholestasis, as could 
occur because of gallstones or tumors, and causes accumulation of bile acids and other compounds in the liver and in plasma. In 
order to discriminate systemic effects (e.g. inflammatory mediators, hormonal regulation) from organ specific effects of 
cholestasis (e.g. mechanisms of apoptosis), ligation of just one bile duct (partial bile duct ligation, PBDL) can be performed 10, 
11. 
 
The BDL model exhibits similarities and differences with the human cholestatic liver disease. Like humans, rodents 
develop bile duct and septal proliferations, inflammatory cell infiltration and liver fibrosis. However, the BDL model shows a 
more aggressive phenotype of the pathology, characterized by extensive areas of necrosis and formation of regenerative nodules, 
and death occurs within weeks or months (depending on the species) 12. Bile duct ligation is still the most used and better 
characterized model of cholestasis. 
 
Growing availability of genetic mouse models, like the Mdr2 null mice, allows addressing specific questions on biliary 
phospholipid excretion. This model closely resembles the phenotype observed in a subtype of progressive familial intrahepatic 
cholestasis 13. Because of the large use of the BDL animal model, most (if not all) the studies cited in this review refer to it. 
 
Several studies have already assessed mitochondria as relevant organelles in the pathophysiology of liver cholestasis 
14-19. Mitochondria are key components of the cholestatic liver diseases, being involved in several steps of the progression of 
the pathology. Overall mitochondrial function is reduced during experimental cholestasis, and this is associated with an important 
metabolic disturbance, characterized by reduced fatty acid oxidation and ketone body formation, both during short- and long-term 
cholestasis 20, 21. Increased anaerobic glycolisis as a compensatory energy-producing mechanism in the cholestatic liver 17 is 
associated with depletion of glycogen stores 22. 
 
Profound metabolic alterations are also aggravated by inflammatory cell infiltration, release of proapototic factors and 
cell death. Mitochondria play a key role in the cholestatic liver because they link inflammation with apoptosis and energy 
production. Mitochondrial damage is not paralleled by proper mitochondrial biogenesis to promote restoration of mitochondrial 
function. Non-functional mitochondria are important sources of reactive oxygen species (ROS), which in turn can promote the 
onset of apoptosis and are also responsible for the activation of pro-fibrogenic mechanisms 23, 24. This is aggravated by a highly 
hydrophobic cellular milieu due to accumulation of potentially toxic bile acids, which further enhance mitochondrial dysfunction. 
The specific mechanisms involved in the onset and development of mitochondrial dysfunction in liver cholestasis are still 
controversial and will be the focus of this review. 
 
3. IMPAIRMENT OF MITOCHONDRIAL FUNCTION IN CHOLESTATIC LIVER DISEASE 
 
Direct and indirect evidences support a profound alteration of the energy homeostasis during cholestasis 17, 20, 21, 25. 
Major alterations of energy metabolism in experimental cholestasis resemble metabolic alterations observed in patients with liver 
cirrhosis 26. Nevertheless, in the human pathology a systematic assessment of the energy metabolism and mitochondrial 
bioenergetics in patients with cholestasis alone is difficult to be obtained. Thus, experimental data from animal models are 
generally required to get a deep understanding of cholestatic liver disease. 
 
After the onset of cholestasis, bile acids accumulate in the liver promoting cellular signaling but also exerting cytotoxic 
actions in hepatocytes 27. Hydrophobicity of these compounds seems to determine the degree of toxicity, being probably CDCA, 
DCA and litocholic (LCA) acids the most potent molecules in this regard 28. Part of the adverse effects of bile acids on 
mitochondrial bioenergetics could be related to the perturbation of mitochondrial membrane composition, as in fact CDCA and 
LCA can incorporate into mitochondrial membranes and reduce its content in phospholipids 19. Thus, this property of 
hydrophobic/lipophilic bile acids could alter membrane fluidity, Dym, ATP levels and ROS production, and increase the 
propensity to apoptosis. 
 
Accumulation of bile acids negatively affects mitochondrial function and bioenergetics by directly impairing activities 
of the enzyme complexes of the ETC 19. Complex I and III activities in isolated mitochondria were negatively affected in 
presence of less than 100 mM of DCA, CDCA or LCA, and complex IV was also inhibited by bile acids but higher 
concentrations were required 19. These concentrations are within the pathological range found in the liver during cholestasis in 
rodents 29, and support a pathophysiological relevant role of these findings.  
 
In the incubation of isolated rat mitochondria with succinate to assess complex II activity, addition of individual bile 
acids induced a decrease in ATP synthesis, ratio between ATP synthesis and oxygen consumption (P:O ratio), and respiratory 
control index (RCI) 30, 31. In another study, bile acids induced a loss of Dym under similar experimental conditions, and the 
effect was larger using CDCA, DCA and LCA than using less hydrophobic bile acids 30. These findings support our 
experimental observations in long-term bile duct ligated rats. In these studies a decrease in Dym was found in isolated 
hepatocytes by flow cytometry analysis 18 and confirmed in isolated mitochondria by polarographic determination 17. 
 
ADP-stimulated mitochondrial respiration (state 3) is largely affected by bile acids and by cholestasis. In fact, addition 
of individual bile acids suppressed mitochondrial respiration in state 3 using succinate as substrate 30, 31. In an independent 
study, state 3 mitochondrial respiration was also decreased by incubating mitochondria with hydrophobic bile acids using L-
glutamate, succinate, duroquinol or ascorbate/TMPD as substrates 19. 
 
State 4 (non-ADP stimulated) mitochondrial respiration either does not change or increases in long-term cholestasis, as 
previously observed in mitochondria isolated from short-term cholestatic rats and dogs 17, 19, 30, 32, 33. The increase in state 4 
mitochondrial respiration found in some studies could be explained by an increased proton leak through the inner mitochondrial 
membrane, which pushes more electrons throughout the ETC without a parallel raise in ATP synthesis. The observed increase in 
state 4 respiration is already evident at 1 day after bile duct ligation, or even after few minutes after the addition of bile acids in 
vitro 30, 33. A short-term mechanism of ETC uncoupling induced by bile acids has been demonstrated, yet uncoupling protein 2 
(UCP-2) already increases in the liver at transcript level at 4 and 8 days of extrahepatic cholestasis in rats 34. Given a direct 
effect of bile acids on state 4 mitochondrial respiration, it is reasonable to suggest that these compounds could directly modulate 
UCP protein activity, but to date experimental evidence to support this hypothesis is lacking.  
 
Several lines of evidence sustain an overall decrease in mitochondrial function during experimental cholestasis. An 
early study by Ozawa and colleagues showed that various respiratory parameters of liver mitochondria change in response to 
acute biliary obstruction in rabbits 35. Despite a transient increase at 3 h from bile duct ligation, ATP production was already 
reduced at 6 h, reached a minimum level at 24 h, and maintained a plateau level for 7 days 35. More recent studies reported 
biochemical alterations of the mitochondrial function in response to acute and chronic cholestasis. Mitochondrial function 
decreased during short and long-term cholestasis (1 to 6 weeks) in rats 31. In this study it was reported a progressive decrease in 
RCI, oxygen consumption in ADP-stimulated respiration (state 3), and ATP synthesis using succinate or a-ketoglutarate as 
substrates 31. 
 
More recent research confirms some previous findings on mitochondrial respiration in cholestasis. ADP-stimulated 
oxygen consumption and RCI were markedly reduced using glutamate and malate as substrates, but not using succinate 17. Thus, 
after long-term cholestasis there seems to exist a major impairment of complex I activity of the ETC rather than a general 
impairment of the respiratory function. Moreover, some compensatory adaptations of mitochondrial respiration could be 
responsible for maintaining coupling of mitochondrial respiration to ATP synthesis, at least under basal conditions. Despite a 
major overall impairment of the mitochondrial function during long-term cholestasis, the liver seems to cope to a certain extant 
with its metabolic requirements by adaptive hepatomegaly. Accordingly, at 5 weeks of cholestasis, oxygen consumption in 
perfused rat liver does not differ in BDL from sham-operated rats 36. 
 
In the cholestatic liver some substances may exert an inhibitory effect on mitochondrial respiration, decreasing ETC 
activity and ATP synthesis. A progressive decrease in ATP synthesis in isolated liver mitochondria was observed throughout 3 
weeks of cholestasis progression, but the decrease was less marked when ATP synthesis was determined in mitochondria isolated 
from hepatocytes 37. The authors proposed the existence of inhibitory compounds in the liver, which might impact on 
mitochondrial respiration even in competent organelles. In a different study it was found a 34% decrease in ATPase activity in 
the liver after 5 weeks of cholestasis, but this parameter did not change significantly in isolated liver mitochondria 36. This 
discrepancy can be partly explained by the different source of mitochondria, which were from hepatocytes of cholestatic animals 
in the first study and from the whole liver (which includes all liver cells) in the second study. 
 
Controversial results have also been presented about the activity of respiratory complexes. In one study, mitochondrial 
preparations from BDL rats presented significantly higher activity of complex III (+35%), complex IV (+40%) and citrate 
synthase (+25%) than those from sham animals 38. In contrast, in another study cytochrome c oxidase (complex IV) and ATPase 
(complex V) activity did not show any change in cholestatic versus control rats 39. Finally, other data reported a decrease in the 
activity of complexes II, III, IV and V, but no change in citrate synthase activity after 90% ligation of the biliary tree 40. 
 
Mitochondrial function was also decreased in tissues other than the cholestatic liver lobes 40. Kanai and colleagues 
showed that 70% or 90% bile duct ligation produces a decrease in the mitochondrial oxygen consumption in state 3 at 4 weeks 
from the surgical procedure in the obstructed lobes 40. Importantly, after 90% partial cholestasis significant changes were also 
observed in the non-obstructed liver lobe, which included a decrease in the RCI, in the P:O ratio, and in the activities of the five 
respiratory complexes 40. Another study showed decreased mitochondrial respiration in state 3 and RCI in heart mitochondria at 
1 week of BDL in rats 41. These results suggest that compounds (e.g. bile salts) released in the circulatory system during 
cholestasis may produce mitochondrial dysfunction in extrahepatic tissues. 
 
4. MITOCHONDRIAL BIOGENESIS IN CHOLESTATIC LIVER DISEASE 
 
Mitochondrial function and mass have to be tightly regulated at the cellular level because of their vital role in energy 
production, metabolism, and signaling 42. The active process of biosynthesis of new mitochondria - called mitochondrial 
biogenesis - has to cope with the specific energy demand of the cell, so it requires a complex interaction between nuclear and 
mitochondrial genomes. The vast majority of the mitochondrial proteome (1100-1500 proteins, 43 is encoded by nuclear DNA 
(nDNA), but 13 essential proteins of the electron transport chain (ETC) are encoded by the mtDNA. 44. The whole process of 
mitochondrial biogenesis involves synthesis, import, and incorporation of proteins and lipids to the existing mitochondria, as well 
as replication of the mitochondrial DNA (mtDNA). Mitochondrial biogenesis is finely coordinated through the activity of several 
transcription factors at the nuclear level, being the most relevant nuclear respiratory factor 1 (NRF-1) and 2 (NRF-2/GABPa), 
estrogen related receptor a (ERR-a), the nuclear coactivators peroxisome proliferator activated receptor g coactivator 1a (PGC-
1a) and b (PGC-1b), and PGC-1 a -related coactivator (PRC) 44. These proteins promote the transcription of several 
mitochondrial genes in the nucleus, among which mitochondrial transcription factor A (TFAM), B1 (TFB1M), and B2 (TFB2M) 
are critical because they bind mtDNA and control mtDNA genes transcription and replication 45, 46. 
 
During the progression of experimental cholestasis, it was observed an increase in mitochondrial protein content in the 
liver until day 14 after bile duct ligation, consistent with the observed increase in liver mass 47. In turn, in comparison to pair-fed 
rats, mitochondrial mass per gram of liver did not change until day 14, but it decreased by 35% at day 28 47. After long-term 
partial cholestasis - that allows comparisons between obstructed and non-obstructed liver lobes – it was found a decrease in some 
subunits of the ETC in both the obstructed and the non-obstructed lobes 40. The authors proposed that an inhibition of the 
expression of nuclear and mitochondrial genes and/or an accelerated proteolysis might occur 40. Two studies confirmed the 
hypothesis of an impairment of mitochondrial and nuclear genes expression observed during short-term and long-term cholestasis 
16, 17. However, no studies have so far supported the hypothesis that increased proteolysis may be the cause of mitochondrial 
dysfunction during the progression of cholestasis. 
 
A decrease in mitochondrial biogenesis has been reported to appear very early in cholestasis. During the first 3 days of 
bile duct ligation, TFAM transcript and protein levels were lower in cholestatic animals than in control ones 16. Nonetheless, in 
this study control rats were not pair-fed to BDL ones. Our group characterized most of the process that brings about a decrease in 
mitochondrial biogenesis during long-term cholestasis, and found that the problem arises both at nuclear and mitochondrial levels 
17. NRF-2/GABPa levels were markedly decreased in the cholestatic rat liver and NRF-1 seemed to have reduced activity and 
was unable to maintain an active transcription of nuclear encoded-mitochondrial genes. This resulted in a decrease in TFAM, 
which is a target gene of NRF-1 and Nrf-2/GABPa, at mRNA and protein levels. Mitochondria themselves further contribute to 
the reduced biosynthetic potential, since synthesis of mitochondrial proteins in isolated liver mitochondria is largely decreased in 
the cholestatic rat starting from 2 weeks of bile duct ligation 47.  
 
One major event associated to TFAM loss in the cholestatic liver was a marked (i.e. ~65%) decrease in mtDNA/nDNA 
ratio 17. Three different situations can explain this finding: 1) a decrease in the copy number of mtDNA per mitochondrion, 2) a 
loss of mitochondria, which is in turn paralleled by a decrease in mtDNA amount per cell, 3) an increase in cell ploidy, which 
affects the mtDNA to nDNA ratio, independent of absolute abundance of mtDNA in the cell. To check for the third situation, we 
assessed cell ploidy in liver from cholestatic and sham operated-pair fed rats. Our results showed a non-significant increase in 
cell ploidy during cholestasis (unpublished results) that cannot account for the marked reduction (~65%) in mtDNA observed 
after 4 weeks of bile duct ligation 17. According to previous studies, it was found that the decrease in mtDNA observed during 
cholestasis should be ascribed to a loss of mitochondria rather than to a decrease in mtDNA per mitochondria. Indeed, mtDNA 
content per mitochondria did not change throughout progression of cholestasis 40. Taken together, these results suggest that 
mtDNA loss is secondary to an overall deregulation of mitochondrial biogenesis. 
 
A special consideration should be made regarding mitochondrial protein import, a mechanism that promotes renewal of 
functioning organelles. Mitochondrial import is a process mediated by cytosolic chaperones, which allow contact between 
proteins containing mitochondrial target sequences and mitochondrial membrane proteins with receptor function 48. Upon 
recognition by the receptor, the imported protein is channeled through pore membrane proteins of the outer membrane, and 
subsequently of the inner mitochondrial membrane 48. After shuttling, the protein is cleaved by mitochondrial peptidases to give 
rise to a mature form, and then delivered to the correct mitochondrial location. To be imported into the mitochondrion, most 
proteins require ATP, GTP and an active proton-motive force 49, 50. The import pore includes protein translocases of the outer 
membrane (TOMs), which are required to take the initial interaction with cytosolic proteins. Among them, TOM20 shows higher 
affinity for targeting signals contained in the cleavable presequences, and TOM70 is usually required for proteins carrying 
internal targeting signals 48, 51, 52. During the progression of experimental cholestasis in rats, TOM20 levels increase in liver 
mitochondria but TOM70 levels are strongly reduced 17. Regardless possible compensatory mechanisms, loss of TOM70 in 
cholestatic liver could have an important impact on mitochondrial biogenesis and bioenergetics. Deletion of TOM70 in yeast 
demonstrated that this receptor has a role as docking site for cytosolic chaperones and also maintains solubility of proteins 
targeted to the mitochondrion 53. Indeed, a yeast mutant in TOM70 shows a reduced import of several mitochondrial proteins, 
including ATPase subunits and the chaperone Hsp60 53. In agreement with this report, Hsp60 decreases in liver mitochondria 
from cholestatic rats at 2 and 4 weeks after bile duct ligation, in association with the decrease in TOM70 17. 
 
We also found that other mitochondrial proteins are differently regulated in the cholestatic liver. TFAM levels are 
largely decreased after 4 weeks of bile duct ligation, even to a greater extent than the decrease in the mRNA level 17. So far, it is 
unclear if there is a specific role for protein degradation in this regard. Eventually, TFAM depletion could be secondary to a 
decreased mitochondrial import, as evidenced by a decreased level of other mitochondrial proteins. Defects in mitochondrial 
protein import could indeed contribute to the development of the disease.  Nonetheless, whatever the relevant mechanism in 
cholestasis, loss of mitochondrial proteins is not a general phenomenon. In fact, cytochrome c is a specific example of a 
mitochondrial protein that may even increase during cholestasis 17. To date, specific studies aimed at understanding the 
contribution of altered mitochondrial import machinery to the defective mitochondrial biogenesis and bioenergetics in the 
development of cholestatic liver disease are lacking. 
 
5. MITOCHONDRIAL-MEDIATED APOPTOSIS IN CHOLESTATIC LIVER DISEASE 
 
5.1. General aspects 
Apoptosis is a ubiquitous form of programmed cell death occurring in human liver diseases 54-57. Hallmarks of 
apoptosis are cytoplasmic shrinkage, chromatin condensation, nuclear fragmentation, presence of plasma membrane blebbing, 
and fragmentation of the cell into apoptotic bodies 58. Upon completion of the process, ordered resorption of individual 
unwanted or dangerous cells minimizes leakage of intracellular components into the extracellular space and attenuates 
inflammatory responses. Apoptosis is generally initiated by external stimuli converging on death receptors (DRs) like tumor 
necrosis factor (TNF) receptor superfamily, member 6 (FAS/APO1/CD95) or TNF (ligand) superfamily, member 10 
(TRAIL/APO2L), that oligomerize and lead to the formation of a death initiating signaling complex (DISC) consisting of Fas 
(TNFRSF6)-associated via death domain (FADD) and an initiator caspase, pro-caspase 8/10 59. In type I cells, processed 
caspase-8 is able to directly activate other effector caspases (i.e. CASP-3, 6 and 7), which in turn trigger the execution of 
apoptosis of the cell. Conversely, in type II cells caspase-8 mediates the activation of the BH3 interacting domain death agonist 
(BID) leading to the activation of BCL2-associated X protein (BAX) and/or BCL2-antagonist/killer 1 (BAK) to the 
mitochondrion, the release of pro-apoptotic factors from mitochondria, formation of the apoptososme, and then activation of 
caspase-9 and effector caspases 60, 61. In the latter case, a mitochondrial amplification loop becomes essential to the execution 
of apoptosis. 
 
Hepatocytes have for long time been considered type II cells because experimental evidences supported the notion that 
CASP-3 is activated through the mitochondrial pathway in these cells 62. Nonetheless, more recent research defines that 
hepatocytes behave as type I (mitochondrial-independent apoptosis) or type II cells (mitochondrial-dependent apoptosis) 
depending on the intensity of the apoptotic stimulus 63, 64. In one study it has been shown that loss of X-chromosome linked 
inhibitor of apoptosis (XIAP) or an increase in second mitochondria-derived activator of caspases (SMAC/DIABLO) in mice 
rendered hepatocytes susceptible to apoptosis independent of BID upon Fas stimulation, like type I cells 63. In another study it 
has been proposed that BID is an amplifier of a weak DR signal, and upon increased Fas stimulation, quiescent and non-quiescent 
hepatocytes are more sensitive to Fas ligand-induced (FasL-induced) apoptosis. Furthermore, hepatocytes’ cross-talk with the 
extracellular matrix can switch the mode of apoptosis from type II to type I. Hepatocytes cultured on collagen, which more 
closely resemble physiological conditions, undergo mitochondrial-independent apoptosis upon FasL stimulation 65. Thus, despite 
a recognized paramount role for mitochondria in the induction of apoptosis in hepatocytes, they can undergo apoptosis also in a 
mitochondrial-independent fashion depending on the intensity of the stimulus and on the interaction with the extracellular 
environment. 
 
5.2. Apoptosis in liver cholestasis: time course and mechanisms 
Liver injury during cholestasis is characterized by hepatocyte and cholangiocyte apoptosis. Caspase-3 immunostaining 
and activity have been previously used to assess the evolution of apoptosis in the cholestatic rat liver. These results showed that 
apoptosis is significantly elevated during the first week after bile duct ligation, declining thereafter 66, 67. Though probably less 
abundant, apoptosis is still present in the cholestatic liver during mid- and long-term evolution of the disease 17, 18. Indeed, flow 
cytometric evaluation of apoptosis in isolated hepatocytes from cholestatic rat liver revealed that apoptosis is still significant at 4 
weeks from bile duct ligation 18. 
 
During progression of cholestasis, multiple mechanisms of apoptosis are likely to act synchronously to promote cell 
death in the liver parenchyma. At three days from the onset of cholestasis, apoptosis in the liver seems to be predominantly Fas-
dependent as assessed by a reduced level of apoptosis in Fas-deficient lpr (lymphoproliferation) mice 68. Nonetheless, at day 7 
from the bile duct ligation, apoptosis was attenuated to a lesser extent in Fas-deficient mice, indicating that other mechanisms 
were promoting apoptosis after bile duct ligation 68. Consistent with molecular alterations of mitochondrial physiology, 
mitochondrial-dependent mechanisms are largely contributing to cell death after bile duct ligation. An alteration of the ratio 
between BAX and B-cell CLL/lymphoma 2 (BCL-2), which peaks at 3 days after bile duct ligation, has been described during 
cholestasis in rats 69. Despite the majority of apoptosis fades away at the end of the first week from bile duct ligation, residual 
liver apoptosis is still detectable after 2 weeks, with increased BAX/BCL-2 ratio and cleaved caspase-3 in rat liver 17. 
 
Further evidence supports a central role of the mitochondrion as a contributor to the apoptotic response in the 
cholestatic liver. Loss of mitochondrial membrane potential (Dym) during long-term cholestasis has been clearly demonstrated 
by two independent techniques, namely flow cytometry and polarography 17, 18. Under proapoptotic stimuli, opening of 
mitochondrial permeability transition (MPT) pores develops and causes collapse of the Dym with release of propoaptotic factors 
that bring about apoptosome formation and caspase activation. In isolated mitochondria from rat liver, chenodeoxycholic acid 
(CDCA) has been found to be a direct inducer of MPT, accompanied by membrane depolarization, release of matrix calcium, and 
osmotic swelling 70. Other hydrophobic bile acids are similarly able to cause mitochondrial depolarization and MPT in isolated 
mitochondria 30, 71-73, thus creating a direct link between bile acids and mitochondrial-mediated apoptosis. In this regard, 
mitochondria are likely to play a key role in apoptosis progression and during long-term cholestasis. A direct causal effect of 
hydrophobic bile acids on Dym has also been demonstrated in different studies using isolated hepatocytes 74, 75 or HepG2 
hepatocytes 76. After bile duct ligation, Bid promotes apoptosis in wild type and Fas-deficient mice, and Bid antisense 
administration to wild type mice promotes a reduction of apoptosis and serum AST levels 75. Similarly, Bid antisense reduces 
apoptosis in GCDC treated hepatocytes 75. Despite clear evidence of the involvement of the mitochondrial pathway during 
cholestasis-induced apoptosis, the role of Bid can be controversial (see section 4.4), and more studies are needed to clarify the 
role of this pro-apoptotic protein in chronic cholestasis. 
 
5.3. Bile acids promote apoptosis in liver 
Primary bile acids are synthesized exclusively in the liver using cholesterol as precursor. In the intestine, bacterial flora 
further processes these compounds to form secondary bile acids, which also have relevant roles in mitochondrial-dependent cell 
death. Given that bile acids accumulate in the liver and in plasma during cholestasis, they are likely to play an important role in 
the progression of the pathology 77-79. High concentration of potentially toxic bile acids in the liver can elicit diverse necrotic 
and apoptotic mechanisms, likely independent of the detergent action of bile acids 27. Exposure of primary hepatocytes and 
hepatocyte cell lines to bile acids promotes cell death by either apoptosis or necrosis, depending on the concentration of these 
compounds 74, 75, 77. The mechanisms whereby bile acids damage hepatocytes are not fully understood. However, they are able 
to promote apoptosis by stimulation of both extrinsic (i.e. DR-mediated) pathways 68, 80 and intrinsic (i.e. mitochondrially-
mediated) mechanisms of apoptosis 75. 
 
Bile acids are direct inducers of apoptosis in hepatocytes through ligand-dependent and ligand-independent activation 
of Fas 77. GCDC treatment increases oligomerization of Fas, recruitment of FADD, mitochondrial permeabilization and 
activation of effector proteases, in the absence of detectable FasL mRNA 77. In McNtcp.24 cells, which resemble hepatocyte 
behavior, GCDC promotes intracellular trafficking of Fas by a Golgi- and microtubule-dependent pathway, to finally increase Fas 
density on the plasma membrane 81. 
 
The hydrophobic bile acid glycochenodeoxycholate (GCGC) has been proposed to be a key player in the induction of 
hepatocyte apoptosis, because exposure of hepatocytes to GCDC results in the induction of cell surface receptor TRAIL-R2/DR5 
at transcriptional level, and also inactivation of FADD-like apoptosis regulator (cFLIP/cFLAR) by phosphorylation 75, 82, 83. 
Thus, GCDC dually sensitizes hepatocytes to cell-induced apoptosis. Bile acids are important mediators of the apoptotic 
response, as TRAIL alone does not induce cell death in normal hepatocytes 75. During experimental cholestasis induced by bile 
duct ligation, hepatocytes overexpress TRAIL-R2 and are sensitized to exogenous administration of TRAIL 84. Accordingly, 
both hepatocyte apoptosis and liver injury are significantly reduced in TRAIL null mice during cholestasis 80. 
 
Thus, death receptors such as Fas and TRAIL-R2 are involved in liver injury induced by cholestasis. Livers from mice 
deficient in Fas exhibited less cell death by necrosis and apoptosis as well as reduced fibrosis after bile duct ligation 68, 85. 
Collectively, these data suggest that GCDC-induced hepatocyte apoptosis involves ligand-independent oligomerization of Fas, as 
it occurs without significant elevations of FasL levels 81. 
 
5.4. Anti-apoptotic response to cholestatic injury 
Cell injury triggers not only apoptosis but also a pro-survival response, which is dependent on different mechanisms of 
regulation, either at transcriptional or post-transcriptional level. After bile duct ligation, activation of nuclear factor-kappa B (NF-
kB) in hepatocytes promotes expression of anti-apoptotic proteins and survival 66, whereas overexpression of IkB (a NF-kB 
repressor) in the liver increases apoptosis and liver damage 67. NF-kB-mediated survival was dependent on the regulation of 
anti-apoptotic genes A1/Bfl and cIAP2 at the transcriptional level. Apparently, bile acids are direct mediators of this pro-survival 
response 66, 86. An increase in the level of the anti-apoptotic BCL-2 has also been observed in liver mitochondria during the 
progression of the pathology 17, 69, possibly to withstand the increase in Bax incorporation in the mitochondrial membrane. 
 
At an early stage of cholestasis some kind of resistance to cell death may develop. During this early stage, increased 
cardiolipin content in the mitochondrion alters the composition of the mitochondrial membrane and decreases the probability of 
MPT pore formation, and the threshold of apoptosis increases 87. Another adaptive response against cell death that accounts for 
apoptosis resistance is the phosphorylation of Bid, which impairs truncation (tBid) and activation of the protein and hence the 
promotion of apoptosis 88. Paradoxically, mitochondrial dysfunction observed during cholestasis might act as a defense 
mechanism against bile acids toxicity. In HCT-116 colon carcinoma cells, inhibitors of complex I, III and V largely decrease 
deoxycholic acid (DCA)-induced cell apoptosis 89. Thus, several mechanisms of mitochondrial and extra-mitochondrial origin 
cooperate to confer resistance against apoptosis in the liver, but risking to maintain damaged (potentially dysfunctional or even 
malignant) cells alive. 
 
Despite apoptosis is largely considered a process to restore liver function homeostasis, there is a strong mechanistic 
link between hepatocyte apoptosis, inflammation, and fibrosis in chronic liver diseases. Engulfment of apoptotic bodies by 
phagocytic cells leads to their activation and in turn to secretion of chemokines as well as recruitment of leukocytes and 
inflammatory cells into the liver 90-92. Apoptosis contributes to hepatic fibrogenesis through activation of hepatic stellate cells 
(HSC) by direct and indirect mechanisms related to the destiny of apoptotic bodies. Phagocytosis of apoptotic bodies by Kupffer 
cells results in the release of transforming growth factor b (TGF-b), which activates HSC 93. If HSC are responsible for 
phagocytosis of the apoptotic bodies then the up-regulation of TGF-b in the same HSC leads directly to their activation through 
an autocrine mechanism 94. Indeed, engulfment of apoptotic bodies by HSC is a stimulus for HSC activation and cause secretion 
of increasing amounts of collagen, leading to liver fibrosis 91. 
 
6. MITOCHONDRIAL OXIDATIVE STRESS IN CHOLESTATIC LIVER DISEASE 
 
Oxidative stress is a common feature of obstructive cholestasis 95, primary biliary cirrhosis 96, 97, and sepsis-induced 
cholestasis 98, and it has been linked to the progression of cholestatic liver injury. During cholestasis, oxidative stress is a 
systemic phenomenon since lipid peroxidation increases in plasma, kidney, brain and heart from rats at 24 h after bile duct 
ligation 99. Oxidative stress is the imbalance between pro-oxidant agents and antioxidant agents in favor of the formers 100. 
Increases in oxidized glutathione (GSSG) – an index of glutathione oxidation -, 8-hydroxy-2’-deoxyguanosine – an index of 
DNA oxidation -, and lipid oxidation occur in rat liver at 15 days of bile duct ligation or thereafter 101-103. 
 
Hepatic GSH is depleted in long term cholestasis 18, 102 due to lower GSH synthesis and down-regulation of GSH 
synthetic enzymes 18, 104. During cholestasis, tumor necrosis factor alpha (TNF-a) and toxic bile acids have been involved in 
liver injury and hepatocyte apoptosis 68, 80. It is known that mitochondrial glutathione depletion sensitizes hepatocytes to 
apoptosis induced by TNF-a 105. In the long term cholestasis there is depletion of reduced glutathione (GSH) in liver 
mitochondria 18 and consequently hepatocytes should be prone to cell death under this condition. Oxidative stress is especially 
marked in liver mitochondria in the long term experimental cholestasis, i.e. at 14 days after bile duct ligation or thereafter, as 
evidenced by a remarkable increase in lipid peroxidation and GSSG together with depletion of GSH 18, 101, 106. Furthermore, 
high-fat diets increased lipid oxidation in liver mitochondria and hepatic injury after bile duct ligation 107. 
 
Nrf2, nuclear factor erythroid derived 2 like 2 (Nrf2) is one of the transcription factors regulating inducible and 
constitutive gene expression mediated by the antioxidant response elements (ARE), which are found in the promoter regions of 
two major detoxication enzymes, namely glutathione S-transferase A2 (GSTA2) and NADPH:quinone oxidoreductase (NQO1) 
108. It is noteworthy that toxic bile acids induce a switch from Nrf2 to c-avian musculoaponeurotic fibrosarcoma/V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog G (c-Maf/MafG) ARE nuclear binding, leading to decreased expression of 
GSH synthetic enzymes and contributing to liver injury during chronic cholestasis 104. Ursodeoxycholic acid (UDCA) and S-
adenosyl methionine treatment prevented this decrease preserving GSH levels and preventing liver injury 18, 104. The beneficial 
effects of UDCA are mediated by activation of the PI3K/Akt/Nrf2 pathway 97, 109, 110. In agreement with an important 
contribution of oxidative damage to the progression of the cholestatic diseases, pretreatment with vitamin E significantly 
diminished mitochondrial lipid peroxidation and hepatocyte damage in rats receiving intravenous taurochenodeoxycholic acid 
(TCDCA) 111. The antioxidants idebenone – a coenzyme Q analogue - or a-tocopherol inhibited the generation of reactive 
oxygen species (ROS) in isolated rat liver mitochondria and in isolated hepatocytes as well as the mitochondrial membrane 
permeability transition and subsequent apoptosis induced by GCDCA in rat hepatocytes 74, 112. Summarizing, these data 
support the relevancy of ROS in liver cholestasis. 
 
Mitochondria are likely major producers of ROS during cholestasis. In agreement, adenoviral therapy to overexpress 
MnSOD was more effective than Cu/ZnSOD to reduce liver damage, fibrosis and 4-hydroxynonenal (a marker of lipid 
peroxidation) 113. Nevertheless, these findings cannot exclude a significant role of other sources of ROS in cholestatic injury 
apart from liver mitochondria. Accordingly, inhibition of the ROS generating enzyme xanthine oxidase by oxypurinol reduced 
hepatocellular injury after bile duct ligation in rats without affecting mitochondrial lipid peroxidation 114. These authors 
suggested that a component of cholestatic injury might be caused by oxidative stress from a source outside of the hepatocyte. In 
this regard, the increase in plasma homocysteine that occurs after bile duct ligation may contribute to oxidative stress and tissue 
damage 115.  
 
In contrast to these results, Baron and Muriel reported that treatment with the antioxidants vitamin E or trolox 
prevented the increase in lipid peroxidation and GSSG levels in the liver without affecting tissue injury assessed by serum 
enzyme activities and histology after 7 days of bile duct ligation in rats 116. This apparent controversy might be explained by the 
adaptive response that occurs in the liver in the short term of cholestasis, evidenced by the increase in hepatic GSH levels at 1 
and 5 days after bile duct ligation 102, which may uncouple oxidative stress and tissue damage at this stage. In addition, the 
experiments mentioned previously on the beneficial effects of vitamin E were performed in hepatocytes in vitro or in perfused 
liver, whereas the experiments by Purucker and colleagues were performed in vivo. 
 
Mitochondrial ROS trigger signal transduction pathways under physiological conditions, but in excess they promote 
oxidative stress and oxidative damage. Bile acids such as DCA and taurodeoxycholic acid (TDCA) increased mitochondrial ROS 
production in hepatocytes 117. Mitochondrial ROS may also cause inactivation of protein tyrosin phosphatases (PTPase) that 
triggers tyrosin phosphorylation of the epidermal growth factor receptor ERBB1 and subsequently activation of mitogen-
activated protein kinase kinase 1/2 and mitogen-activated protein kinase 1/2 (MEK1/2-ERK1/2) 117. Activation of the ERK1/2 
and AKT pathways by bile acids protects against hepatocyte apoptosis through reduction of the FAS-R-caspase 8/9/3 pathway 
118, 119. Activation of these pathways was abolished in Rho 0 cells or by cyclosporine A and bongkrekic acid, which inhibit 
mitochondrial permeability transition and electron transport 117.  
 
However, this protection is ineffective during chronic cholestasis due to generation of large amount of mitochondrial 
ROS. In turn, ROS could contribute to maintain apoptosis active, as observed during long-term cholestasis 17, 18. Bile acid 
toxicity in hepatocytes seems to be dependent on the generation of mitochondrial ROS and accordingly, UDCA reduced DCA-
induced hepatocyte killing at least in part by inhibiting DCA-induced mitochondrial permeability transition and ROS generation 
72, 73. Chronic oxidative stress may also contribute to apoptosis by inducing a severe depletion of mitochondrial cardiolipin 
content found in the long term cholestasis 18. Cardiolipin normally protects against apoptosis by providing an increased pool of 
negative ions that bind Ca2+, thereby preventing it from binding to protein sites that induce opening of mitochondrial 
permeability transition pores 120. 
 
Dent and coworkers 117 proposed that during reabsorption of bile acids with nutrients after feeding, bile acid-induced 
mitochondrial ROS modulate AKT/glycogen synthase activity as well as ERK1/2/LDL receptor helping in the regulation of 
glucose and lipid metabolism. However, during chronic cholestasis prolonged exposure to high concentrations of bile acids 
causes oxidative stress, uncoupling growth factor receptors from protective downstream signaling pathways 117. Thus, marked 
glutathione depletion and oxidation as well as lipid peroxidation occur in liver mitochondria upon chronic cholestasis 18, 106 
without activation of the AKT pathway 17. It is worth noting that the mitochondrial concentration of GSH exhibited a positive 
correlation with the activity of some respiratory chain complexes, particularly with succinate:ferricytochrome c oxidoreductase, 
whereas the mitochondrial concentration of thiobarbituric acid reacting substances (TBARS) - as an index of lipid peroxidation - 
showed a negative correlation. Serum ALT and alkaline phosphatase activities as well as bilirubin levels correlated significantly 
with mitochondrial levels of conjugated dienes and TBARS 107. Furthermore, the beneficial effects of UDCA in the treatment of 
chronic cholestasis are associated with a partial prevention of both glutathione depletion and oxidation in liver mitochondria as 
well as with a decrease in mitochondrial ROS generation 18. 
 
In addition, oxidative stress contributes to the onset and progression of liver fibrosis induced by chronic cholestasis 24. 
ROS and lipid peroxidation products, such as 4-hydroxynonenal, promote fibrogenesis through redox signalling that leads to up-
regulation of the transforming growth factor beta, activation of HSC, and modulation of the expression of metalloproteinases and 
their specific inhibitors 24, 121. 
 
Oxidative stress and particularly the increased mitochondrial ROS production that occurs in biliary cirrhosis 18 should 
induce mitochondrial biogenesis through activation of NRF-1 and PGC-1a 122. Indeed, oxidative stress normally induces NRF-1 
phosphorylation and up-regulation of TFAM expression via phosphatidylinositol 3-kinase (PI3K) and AKT/protein kinase B 123. 
However, AKT was not phosphorylated and PGC-1a and TFAM were down-regulated in biliary cirrhosis avoiding the 
stimulation of mitochondrial biogenesis through this pathway 17.  
 
In addition to be a consequence of cholestasis, oxidative stress can also promote cholestasis on its own 124. Oxidative 
stress impairs the hepatocyte capability to secrete and retain bile salts in the bile canaliculus and induces actin-cytoskeletal 
disarrangement causally linked to internalization of canalicular transporters and disarrangement of tight-junctional structures 124. 
Indeed, oxidative stress triggers reversible retrieval of the multidrug resistance-associated protein 2 (Mrp2), a biliary transporter 
involved in bile salt-independent bile flow, from the canalicular membrane of hepatocytes and its translocation into cytosolic 
putative vesicles via the redox-sensitive balance of protein kinase A/C (PKA/PKC) activation 125. 
 
7. DUAL ROLE OF INFLAMMATION IN CHRONIC CHOLESTASIS 
 
In cholestasis the accumulation of bile acids – especially hydrophobic ones - causes hepatocyte injury that results in the 
activation of Kupffer cells and infiltration of other inflammatory cells into the liver, particularly neutrophils 126. This second 
phase of generalized injury triggered by the innate immune system aggravates liver injury promoting fibrosis and eventually 
chronic liver failure 80, 85. Consequently, long term cholestasis is a chronic inflammatory condition characterized by liver 
fibrosis together with maintained expression of pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) 17, 126, 
127. 
 
Inflammation seems to play a dual role in the development of liver damage during cholestasis. On the one hand, 
neutrophils and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) significantly promote liver injury after bile duct 
ligation, whereas on the other hand Kupffer cells protect against cholestatic liver injury 128. TRAIL is a death ligand released by 
cells of the innate immune system - especially natural killer cells, natural killer T cells, and monocytes - which plays a key role in 
liver injury during cholestasis 80. Accordingly, apoptosis was markedly reduced in TRAIL knockout mice subjected to bile duct 
ligation, and it was associated with reduced liver fibrosis and serum ALT values 80.  
 
Kupffer cells play distinct roles in the cholestatic liver disease. Phagocytosis of apoptotic bodies by Kupffer cells 
results in the release of TGF-b,  which activates HSC 93. Nevertheless, Kupffer cell-depleted mice and interleukin-6-deficient 
mice exhibited more liver injury, particularly necrosis, than wild type animals after bile duct ligation 128. It was suggested that 
Kupffer cells produce cytokines, chemokines and toxic products that would contribute to hepatocyte death, inflammatory 
infiltrate and activation of HSC 129, 130. However, Kupffer cells reduce cholestatic liver injury by cytokine-dependent 
mechanisms that mainly involve secretion of interleukin 6 128. Indeed, exogenous IL-6 completely reversed the consequences of   
 
Kupffer cell depletion 128. It seems that Kupffer cells protect against the increase in bacterial endotoxin derived from 
the gut that occurs during cholestasis due to impairment in the integrity of the intestinal mucosa 131. 
 
Pro-inflammatory cytokines, particularly TNF-a and interleukin-2, are potent inducers of intrahepatic cholestasis 132. 
Indeed, TNF-a inhibits bile flow and hepatocellular bile salt uptake in the rat 133, 134. This inflammation-induced cholestasis 
results mainly from inhibition of expression and function of hepatocellular transport systems for bile salts 132. Consequently, 
chronic inflammation associated with chronic cholestasis may generate a deleterious positive feed-back mechanism that 
potentiates each other. 
 
However, the role of TNF-a in chronic cholestasis is dual and paradoxically this pro-inflammatory cytokine seems to be 
more beneficial than detrimental. TNF-a may promote hepatocyte apoptosis via TNFRSF1A-associated via death domain 
(TRADD), receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIP), and mitogen-activated protein kinase 8 and 9 (JNK1 
and JNK2) 135 and thus aggravate cholestasis 132, but paradoxically TNF-receptor-deficient mice subjected to chronic 
cholestasis showed enhanced hepatocellular necrosis 127. TNF-a protects by inducing the expression of multidrug resistance-
associated protein 3 expression on the basolateral membrane of hepatocyes, favoring the efflux of bile salts and glucuronide 
conjugates 127. In addition, TNF-a may also trigger activation of an anti-apoptotic pathway mediated by NF-kB transcription of 
survival genes, such as growth arrest and DNA-damage-inducible protein beta (GADD45beta), manganese superoxide dismutase 
(MnSOD), and CASP8 and cFLIP/cFLAR 135. 
 
8. CHOLESTATIC LIVER DISEASE AS A SECONDARY MITOCHONDRIOPATHY 
 
Disorders that affect mitochondrial oxidative phosphorylation usually have an important impact on cellular metabolism, 
leading to liver diseases and often to multisystem alterations, and they have been called mitochondrial hepathopaties 136. They 
have been divided into primary disorders 137, 138, in which the mitochondrial defect is the primary cause of the liver disease, 
and secondary disorders that are caused either by genetic defects originally of non-mitochondrial proteins or by acquired injury to 
mitochondria 139. Most primary mitochondrial hepatopathies are caused by mutations in nuclear genes, such as mitochondrial 
polymerase g (POLG), rather than by deletions or rearrangements of mitochondrial DNA 136. They include electron transport 
defects, fatty acid oxidation and transport defects, disorders of the mitochondrial translational process, urea cycle enzyme 
deficiencies and phosphoenolpyruvate carboxykinase deficiency 136. Among them, the mitochondrial DNA depletion syndrome 
should be highlighted because it is characterized by a dramatic reduction in the mtDNA copy number in different tissues (< 10% 
of the normal amount of mitochondrial DNA vs nuclear DNA), insufficient synthesis of mitochondrial complexes I, II, IV, and V, 
together with lactic acidosis, cholestasis, steatosis, and fibrosis 136. 
 
It is well known that severe mitochondrial dysfunction occurs in chronic cholestasis in rodents and in humans. Indeed, 
this liver disorder leads to a marked loss of Dym as well as to decreased ATP production, fatty acid oxidation, and ketone body 
formation 18-21, 140-142. In addition, cholestasis and progressive liver fibrosis have been associated with mtDNA depletion in 
infants 143. Recently, we have reported that long-term cholestasis is also characterized by a remarkable reduction in the 
mitochondrial DNA to nuclear DNA ratio, i.e. 35% of the normal ratio 17, probably due to a reduced TFAM protein import. 
TFAM, which regulates mtDNA transcription and replication, also functions as histone-like protein that protects mtDNA. Hence, 
a marked reduction in TFAM levels would lead to mtDNA instability. Accordingly, we have shown that long-term cholestasis 
leads to mtDNA deletions 17. Chronic mitochondrial oxidative stress might be responsible, at least in part, for the increased 
frequency of mtDNA deletions 144. It is noteworthy that somatic mtDNA mutations are associated with hepatocarcinogenesis 
123. 
 
Therefore and taken into account these mtDNA mutations together with the severe mtDNA depletion and 
mitochondrial impairment, we have proposed that long-term cholestasis should be considered a secondary mitochondrial 
hepatopathy 17. Other secondary mitochondrial hepatopathies are Reye’s Syndrome, Wilson’s Disease, valproic acid 
hepatotoxicity, and liver diseases induced by nucleoside reverse transcriptase inhibitors 136. It is worth noting that identical 
mutations in mitochondrial DNA may give rise to great variations in phenotype and severity due to heteroplasmia 136. Indeed, 
cells may harbor both normal and mutant mitochondrial DNA in various amounts due to random partitioning during cell division. 
 
9. MITOCHONDRIA AS PUTATIVE TARGETS FOR THERAPEUTIC INTERVENTION IN CHOLESTASIS 
 
The knowledge and understanding of cholestatic liver diseases is growing, especially at the experimental level. 
Nonetheless, pharmacological treatments have not evolved so much since the introduction of UDCA as a therapeutic agent. 
UDCA is one of the major compounds found in the bear bile and it is currently used for curing hepatic and biliary disorders. Bear 
bile has been used in traditional Chinese medicine for thousands of years, because it was found to have a wide range of 
pharmacological actions with little toxicological side effects. Professor Olof Hammarsten from the University of Uppsala 
(Sweden) was the first to isolate an unknown bile acid from the bile of the Polar bear and named it “ursocholeinsäure”, later 
renamed ursodeoxycholic acid by Prof. Shoda 145. Since mid 1950’s, Japanese scientists succeeded in chemically synthesizing 
UDCA from cholic acid 146, which is currently made synthetically in large quantities and widely used in Western medicine. 
Nowadays, UDCA is the only drug approved by the Food and Drugs Administration (FDA) for the treatment of primary biliary 
cirrhosis (PBC) patients without liver transplantation. The efficacy of UDCA for treatment of recurrent PBC after liver 
transplantation remains less well known. 
 
Putative mechanisms of action of UDCA (or its taurine-conjugated form TUDCA) include: anti-apoptotic 147, 148, 
regulation of immune function 149, 150, anti-inflammatory 151, promotion of choleresis 152-154, coordination and maintenance 
of mitochondrial integrity 18 and alteration of cell signaling 155, 156. Despite several relevant studies in vivo with animals and in 
vitro with cells and isolated organelles (e.g mitochondria), still poor is the knowledge of the mechanisms of action of this 
molecule in the human being. UDCA has been proposed to protect hepatocytes by decreasing mitochondrial peroxide production 
in BDL rats 18, a mechanism that probably contributes to the anti-apoptotic action of UDCA. UDCA could have a have a 
beneficial role by increasing antioxidant defenses in liver cells 157. This mechanism of protection is supported by experimental 
evidence with PBC patients 97. Kawata K. and collaborators studied a group of 13 PBC patients before and after UDCA 
treatment. Compared with pre-treatment, UDCA was able to increase total and phosphorylated levels of Nrf-2. This was 
associated with an increase in the levels of thioredoxin (Trx) and thioredoxin reductase 1 (Trxr1), the only enzyme in charge of 
reducing Trx using NAPDH as a cofactor 97. These findings support previous experimental knowledge of an antioxidant effect of 
UDCA 18, 157. Thus, by this mechanism UDCA is suggested to protect mitochondria from oxygen radical-induced dysfunction. 
Other mechanisms through which UDCA ameliorates liver function in humans are yet to be established. 
 
Given the clear implication of mitochondrial dysfunction in the progression of cholestatic liver diseases, novel 
therapeutic approaches could be considered. Selective delivery of mitochondrial antioxidants such as MitoQ - or related 
compounds 158-160 -, could be considered alone or in combination with UDCA. MitoQ, which consists of a quinone/quinol 
moiety linked to a triphenylphosphonium (TPP) moiety through an alkyl chain 159, easily passes through the phospholipid 
bilayer and accumulates in the mitochondrial matrix driven by the Dym 161. MitoQ is an effective antioxidant against lipid 
peroxidation 162, 163 and peroxinitrite formation 164, but minor is its reactivity towards hydrogen peroxide 164. This compound 
has been shown to have other biological activities, such as preventing the loss of Dym and decreasing caspase activity in 
response to apoptotic stimuli 162. Conversely to MitoQ, uptake of other mitochondrial antioxidants like SS peptides 
(tetrapeptides with alternating aromatic residues and basic amino acids) was shown to be almost independent of Dym. These 
compounds also have important scavenging effects and can be used to reduce apoptosis 160. 
 
Long-term oral administration of MitoQ to mice, rats and humans has been proven to be safe 165-167. After oral 
administration, it accumulates in heart, liver, kidney, skeletal muscle, brain and fat 165.  Experimentally, this mitochondrial 
antioxidant has been successfully used to protect against cardiac ischemia reperfusion (I/R) injury in rats 168 and mice 169, 
increased blood pressure in spontaneously hypertensive rats 170, and organ damage in a lipopolysaccaride-peptoglycan model of 
sepsis 171. In humans, MitoQ has been used to treat chronic hepatitis C virus (HCV), a disease with evidence for increased 
oxidative stress and mitochondrial damage 172. In this study MitoQ was proven effective to reduce hepatic damage (assessed as 
serum ALT), without alteration of the viral load. Because of the safety of this mitochondrial antioxidant, MitoQ could be a 
possible therapeutic approach to test for the treatment of cholestatic liver diseases, which have been shown to be associated with 
high levels of mitochondrial oxidative damage. 
 
In conclusion, mitochondrial dysfunction may cause oxidative stress, apoptosis and fibrosis. Mitochondrial dysfunction 
is also central to a severe metabolic alteration in the cholestatic liver, a condition worsened by a defective induction of 
mitochondrial biogenesis at nuclear and mitochondrial level. Therapeutic approaches to treat the cholestatic liver and associated 
diseases (like PBC) rely on the partial and not well understood efficacy of UDCA, the only approved treatment at present. A 
more targeted antioxidant therapy to rescue mitochondrial function, such as MitoQ or other mitochondrial antioxidants, might 
have beneficial effects that complement UDCA treatment. 
 
10. CONCLUDING REMARKS 
 
In this review we have focused on the contribution of mitochondria to the pathogenesis of liver disease in long-term 
cholestasis, elucidating the major mechanisms known so far to explain the mitochondrial impairment in this chronic disease. In 
particular, the contribution of inflammation and apoptosis as well as the lack of stimulation of mitochondrial biogenesis, the 
marked mitochondrial DNA depletion and occurrence of mitochondrial DNA mutations to the progression of this severe disease 
have been highlighted. All these findings certainly support the consideration of long term cholestasis as a secondary 
mitochondrial hepatopathy. 
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Figure 1. Bile acids together with death ligands receptors (Fas and TRAIL-R2/DR5) casuse apoptosis in hepatocytes during bile 
duct ligation. Inflammatory cells promote release of cytokines and death receptors ligands (FasL and TRAIL), which activate 
proapoptotic caspases, truncation of Bid (tBid) and activation of Bax/Bak. Bile acid accumulation in the cholestatic liver 
promotes apoptosis by different mechanisms: a) FADD accumulation on the plasma membrane; b) phosphorylation of cFLIP (an 
anti-apoptotic protein), yielding to an inactive form; c) increase of TRAIL-R2 mRNA, which potentiates the apoptotic stimulus. 
Nonetheless, bile acids also favor survival of the hepatocyte by activation of NF-kB. Mitochondria, stimulated by bile acids 
and/or proapototic Bax/Bak, trigger apoptosis. The result is a loss of mitochondrial membrane potential, decrease in ATP 
synthesis, and increase in ROS production. These mechanisms lead to metabolic alterations, apoptosis, and fibrosis. 
Abbreviations: BAs, bile acids; HSC, hepatic stellate cells; ROS, reactive oxygen species. 
 
Figure 2. Mitochondrial biogenesis is defective during cholestasis. Renewal of mitochondria is brought about by redox-sensitive 
NRF-1 and GABP- a, which promote transcription of nuclear encoded-mitochondrial genes. The dehacetylase SIRT1, which 
participates in the regulation of PGC-1alpha activity, PGC-1a and GABP-a are decreased in the cholestatic liver. PRC and AKT 
do not cooperatively support NRF-1 activity during cholestasis. In this situation transcription of TFAM, POLG, CYCS, and some 
ATPase subunits is blunted, and mitochondrial biogenesis is not effective. Long-term cholestasis is characterized by a marked 
loss of mtDNA and increased frequency of mtDNA deletions. Abbreviations: CYCS, cytochrome c somatic; mtDNA, 
mitochondrial DNA; POLG, mitochondrial polymerase gamma; TFAM, transcription factor A, mitochondrial. 
 
Running title: ???? 
List of required items 
 
Note: This galley is provided to you for text correction. Please read this galley with great care and make all necessary text 
changes. Following submission of the first galley, text changes will not be possible without ordering an entire reprocessing step. 
If required, the form can be obtained at (http://www.bioscience.org/submit.doc).  
 
The following marked items are not provided or formatted according to per FBS style. Please format or provide the item(s) 
indicated below. Details on proper formatting of the document and instruction for obtaining doi linked references is available at 
the end of the publication forms.  
 
 Text.   
 
Change non-English characters to their English correlates. These characters will appear as blank boxes in the text upon 
publication 
Place references within parenthesis at the end of sentences. 
 
 References. Format per FBS style. Do not use automatic numbering of Word for references. All references should be 
numbered manually. Follow the following style for references. All references must be justified to right and left and there should 
be hard return between references as follows.  
 
1. Bart Karl, Peter Thomas: Molecular and cellular adaptation of muscle in response to exercise. Physiol Rev 23, 520-535 (1995) 
  
2.  Bart Marks, Peter Goll. Skeletal muscle adaptability: significance for metabolism and performance. In: Handbook of 
Physiology, Sect 10 Skeletal muscle. Eds: LD Peachey, RH Norbert, SR Finn Bethesda, Maryland (1981) 
 
or  
 
1. B Karl, P Thomas: Molecular and cellular adaptation of muscle in response to exercise. Physiol Rev 23, 520-535 (1995) 
  
2.  B Marks, P Goll. Skeletal muscle adaptability: significance for metabolism and performance. In: Handbook of Physiology, 
Sect 10 Skeletal muscle. Eds: LD Peachey, RH Norbert, SR Finn Bethesda, Maryland (1981) 
 
 Tables. No tables 
 Running title. Provide a running title less than 55 characters. See sample [Running title: Production and reduction of ROS] 
 Figures. Provide per FBS style. Figures should be of high quality and >300 dpi. Submit as fig1.jpg etc. Do not use any other 
filename. Do not include filename or any other name or any white or unused spaces around figure. Crop the figure close to the 
image so that no white space around any figure is visible.  Place multipart figures in a single file. Place labels in the left lower 
corner of each figure. Figures that do not follow the above guidelines can not be used for document processing 
 
 DOI linked references provided within a file named doi.doc. All doi linked references must have live links. Do not paste data 
as text. Paste in native format to maintain the links. Live links will lead to conversion of the cursor to a hand. See sample below. 
Place cursor over doi:10.1002/ijc.20631 and you will note the cursor changes to a hand. All doi in the ref list must have similar 
live links. Follow the steps provided below to obtain the doi with live links. Some references may not have doi. Please disregard 
such results. Such references will be followed by a statement such as [doi not found]. Please do not remove such references from 
the list.  
 
K Almholt, LR Lund, J Rygaard, BS Nielsen, K Danø, J Rømer, M Johnsen: Reduced metastasis of transgenic mammary cancer 
in urokinase-deficient mice. Int J Cancer 113 (4), 525-32 (2005).  
doi:10.1002/ijc.20631 
 
1. Go to http://www.crossref.org/ 
2. Click on “simple text query” in the left column of the page 
3. Copy about 50 references at a time from the referfence list 
4. Paste the references into the query box 
5. Click “submit” button 
6. The doi linked references will be displayed in about 30 seconds on the screen 
7. Copy all the references including those that do not have live doi links by pressing “Control+C” 
8. Paste the data into a blank new document 
9. Repeat this process for other references 
10. Save the file as doi.doc. Do not add any other text to the page (such as DOI references etc) 
11. Submit the file with other items including galley, forms, figures, etc to fbs@bioscience.org.  
 
 
 Publication forms 
 
Please submit all the following together in a single Email to fbs@bioscience.org. Do not send on different dates 
 
1. Galley (do not change the manuscript number). Sample (1435.doc) 
2. Figures. Submit figures as jpg files named fig1, fig2 etc. Do not use any other style such as Fig1 or Fig 1 et. 
3. DOI linked references with tabular format and links. Submit as doi.doc (do not use any other filename) 
4. Publication forms. Submit as forms.doc (do not use any other filename) 
 
Note: The return of this galley requires your approval  
 
I am the corresponding author 
 
1. I have read this galley and have made all necessary text changes 
2. I approve the publication of this galley without any further text changes. 
3. If I wish to request any further changes not included in this galley, I will submit the reprocessing form  
(http://www.bioscience.org/submit.doc). 
 
I provide my approval  
 
Approved  
 
 (click this box and then select “Checked”. The box will change to  
 
Place your name here:    
 
Place your E-mail here: 
 
Place date here:  
 
Manuscript Type: Invited review  
Managing Editor: Marcelo G. Roma   
 
 
 
